Table 2.
Infections.
| Reference | Number of patients | Mean VDZ exposure time (months) | Infectionsa (patients) | Infections (events) | Infections |
|---|---|---|---|---|---|
| Hartery 201610 | 5 | 6.8 | 0 | 0 | \ |
| Lim 201611 | 5 | 8.1 | 0 | 0 | \ |
| Wright 201714 | 10 | 13.1 | 5 | 11 | Pneumonia (1), empyema (2), CD (4), cholangitis(4) |
| Olmedo-Martin 201713 | 2 | 12.0 | 0 | 0 | \ |
| Mumtaz 201612 | 1 | 8.0 | 0 | 0 | \ |
| Peverelle 201815 | 5 | 20.0 | 1 | 1 | CD (1) |
| Drastich 201816 | 2 | 6.0 | 1 | NA | NA |
| Daffra 201717 | 1 | 5.0 | 0 | 0 | \ |
CD: Clostridium difficile; NA: not available; VDZ: vedolizumab.
a
Number of patients who had at least one infection.